Lecanemab 사용 6개월 이내 임상양상 증례보고

• 영문명: Case Report on Clinical Features Within Six Months of Lecanemab Use
• 발행기관: 대한노인정신의학회
• 저자명: 추일한(IL Han Choo)
• 간행물 정보: 『노인정신의학』제29권 제2호, 84~88쪽, 전체 5쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2025.10.30

국문 초록

Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta protofibrils and was approved by the FDA on July 6, 2023. This case report describes the clinical setting for lecanemab administration, as well as the clinical course and adverse events following six months of treatment in four patients with Alzheimer’s disease dementia. These findings may serve as foundational information for future clinical practice and research involving monoclonal antibody therapies for Alzheimer’s disease.

목차

서 론

증 례

고 찰

REFERENCES

키워드

레카네맙 임상 알츠하이머병 치매 Lecanemab Clinical Alzheimer’s disease Dementia

참고문헌

• Int J Mol Sci
• N Engl J Med
• Alzheimers Res Ther
• AJR Am J Roentgenol